| abstract |
(-)-EGCG, the most abundant catechin, was found to be chemopreventive and anticancer agent. However, (-)-EGCG has at least one limitation: it gives poor bioavailability. This invention provides compounds of generally formulae below, wherein R11, R12, R13, R21, R22, R2, R3, and R4 are each independently selected from the group consisting of -H, and C1 to C10 acyloxyl group; and R5 is selected from the group consisting of -H, C1 -C10 -alkyl, C2 -C10 -alkenyl, C2 -C10 -alkynyl, C3 -C7 -cycloalkyl, phenyl, benzyl and C3 -C7 -cycloalkenyl, whereas each of the last mentioned 7 groups can be substituted with any combination of one to six halogen atoms; at least one of R11, R12, R13, R21, R22, R2, R3 and R4 is -H, which were found to be more potent than their non-protected counterparts, which can be used as proteasome inhibitors to reduce tumor cell growth. |